Reckitt account plan
Global leader in hygiene, wellness, and nutrition products for a cleaner, healthier world accessible to everyone.
At a glance
Reckitt is a UK consumer health and hygiene group (Dettol, Lysol, Durex, Finish) with FY2025 net revenue of £14,205mn and about 36k employees.
Reckitt is a UK-headquartered consumer health and hygiene group operating in 80 countries with an average of 36k employees. Its strategic core, Core Reckitt, is built around 11 Powerbrands in four categories: Self Care (Nurofen, Mucinex, Gaviscon, Strepsils), Germ Protection (Dettol, Lysol, Harpic), Household Care (Finish, Vanish) and Intimate Wellness (Durex, Veet). In FY2025 Group net revenue was £14,205mn (+5.0% like-for-like) and adjusted operating profit £3,543mn at a 24.9% margin. Essential Home was sold to Advent on 31 December 2025 (Reckitt keeps a 30% stake), and Mead Johnson Nutrition is managed as non-core while strategic options are assessed. Since 2025 the business is run through three Areas (Emerging Markets, Europe, North America), each with its own P&L.
Business units
Self Care
32% of Core Reckitt net revenue (FY2025, £3,306 million)Over-the-counter health brands Mucinex, Nurofen, Gaviscon and Strepsils, plus vitamins and supplements (Move Free, MegaRed, Neuriva) and Biofreeze. FY2025 grew +3.0% LFL as weak cold and flu seasons hit seasonal OTC; Gaviscon and VMS grew. In Q3 2026 Self Care was £880m, +2.2% LFL.
Germ Protection
32% of Core Reckitt net revenue (FY2025, £3,224 million)Dettol, Lysol and Harpic, which reach one in four households worldwide. Grew +8.4% LFL in FY2025 and +10.5% in H1 2026, led by Dettol and the plant-derived Dettol Activ-Botany launch. Lysol supply was constrained in Q3 2026 by plant upgrades.
Household Care
21% of Core Reckitt net revenue (FY2025, £2,189 million)Finish automatic dishwashing and Vanish stain removal. Declined -0.4% LFL in FY2025 and -6.6% in H1 2026 on Russia sanctions and heavy Auto Dish promotion in Europe; Finish returned to growth in Europe in Q3 2026.
Intimate Wellness
15% of Core Reckitt net revenue (FY2025, £1,515 million)Durex, Veet, Intima and KY. Grew +12.5% LFL in FY2025, slowed to +0.5% in H1 2026 after VAT on condoms in China, then recovered to +6.4% in Q3 2026 with Durex and Veet.
Emerging Markets (Area)
44% of Core Reckitt net revenue (H1 2026)Led by President Emerging Markets Nitish Kapoor. FY2025 net revenue £4,291mn, +14.6% LFL; Q3 2026 £1,174m, +8.0% LFL, with India double-digit and China slowing to mid-single-digit on cross-border VMS headwinds.
Europe (Area)
33% of Core Reckitt net revenue (FY2025, £3,384 million)Led by President Europe Eric Gilliot. Declined -1.4% LFL in FY2025 and -3.0% in H1 2026 in a promotional, value-seeking market, then returned to growth at +0.8% LFL in Q3 2026.
North America (Area)
25% of Core Reckitt net revenue (FY2025, £2,559 million)Led by President North America Jérôme Lemaire; non-seasonal brands (Lysol, Finish, VMS) make up c. 70% of its net revenue. Q3 2026 fell -1.3% LFL as Lysol supply was constrained and retailer orders were phased into Q4.
Mead Johnson Nutrition (non-core)
15% of Group net revenue (FY2025, £2,119 million)Infant and paediatric nutrition including Nutramigen, led by President Nutrition Susan Sholtis. Grew +3.8% LFL in FY2025 and is guided to low-single-digit growth in 2026; Reckitt continues to assess its long-term strategic options.
Strategic priorities
- Core Reckitt growth target
- Core Reckitt is to deliver +4% to +5% like-for-like net revenue growth over the medium term, with annual EPS growth. FY2026 guidance was cut in October 2026 to +3.5% to +4.5%.
- Portfolio streamlining
- Essential Home (£1.9bn net revenue) was sold to Advent on 31 December 2025, the Russia Hygiene divestment is expected to complete in H2 2026, and strategic options for Mead Johnson Nutrition are still being assessed.
- Fuel for Growth cost programme
- Fixed costs fell from 21.8% of net revenue in 2023 to 19.4% in 2025, with a target below 19% by end-2027 for approximately £1 billion of one-off investment over 2024-2027, about £350 million of it in 2026. Remaining levers are shared service hubs in Warsaw, Mexico City and Hyderabad and digital and generative AI.
- Emerging Markets and OTC expansion
- Emerging Markets is the largest Area and is guided to high-single-digit growth for 2026. Reckitt is spreading sales methods from India and China and building its OTC portfolio, led by Gaviscon.
- Brand investment and innovation
- Brand Equity Investment rose to 14.6% of net revenue in 2025 and 15.3% in H1 2026. Recent launches include Mucinex 12HR Cold & Fever, Dettol Activ Botany, Durex Intensity and Vanish Turbo.
- Market share
- 45% of top Category Market Units were holding or gaining share at H1 2026, against a 60% target; Mucinex US and Durex China were the two large units below that line.
Latest results
In H1 2026 (to 30 June) Group net revenue was £6,411m, -8.1% IFRS after the Essential Home sale but +2.6% like-for-like; Core Reckitt grew +2.7% LFL, accelerating to +4.2% in Q2. Core + MJN adjusted operating margin was 23.6% (-100bps) and adjusted diluted EPS 152.1p (-9.7%). In Q3 2026 Core Reckitt net revenue was £2,690m, +3.3% LFL (+3.9% excluding Russia Hygiene): Emerging Markets grew +8.0%, Europe returned to growth at +0.8% and North America fell -1.3% on Lysol supply constraints. FY2026 Core Reckitt guidance was trimmed to +3.5% to +4.5% LFL, with the Core + MJN adjusted operating margin kept at 24.9% to 25.6%.
Investments and deals
- North America investment plan
- Up to $600m multi-year investment announced in September 2026 for U.S.-based innovation, Healthcare access and supply resilience; 400 million builds a new Self Care factory in North Carolina and much of a further 200 million upgrades two hygiene plants.
- China manufacturing and R&D
- Expansion of the Taicang factory and a new Shanghai Science and Innovation Centre, the ninth global innovation hub.
- Capex
- Capex rose to £592 million in 2025 (2024: £465 million), including Mead Johnson regulatory and resilience investment; 2026 capex is guided at around 4% of net revenue.
- Capital returns
- £6.4bn returned to shareholders since July 2024, including a c.£1.6 billion special dividend paid in February 2026, and a new buyback of up to £500 million started on 5 August 2026.
- Supply chain and SAP modernisation
- SAP modernisation is under way, and Reckitt is building strategic inventory of solvents and plastics, moving sourcing and using more post-consumer recycled plastic.
Challenges and risks
- Manufacturing capacity in North America
- Line upgrades at the St. Peters hygiene plant caused longer-than-expected downtime on about four lines in Q3 2026, limiting Lysol supply despite strong demand.
- Middle East input costs
- The Middle East war raised input costs and forced temporary closure of the Bahrain plant; at Q1 a $110 oil scenario implied a c.£130 million - £150 million gross input-cost impact.
- Promotional pressure in European Auto Dish
- European Auto Dish is promotion-heavy and consumers are cutting volumes, with discounters gaining share; Household Care is elastic to price increases.
- China competition
- Cross-border VMS in China was roughly flat in Q3 2026 after false claims by smaller local competitors hurt consumer trust, and Durex was hit by VAT on condoms.
- Heightened principal risks
- The 2025 annual report flags product integrity, supply chain continuity, technology resilience and cyber, and geopolitical instability (tariffs, conflicts, shipping) as heightened risks.
What leadership says
“We have not historically invested as much in manufacturing as a company as I think we need to.”
“We will probably have to price more at this level of commodity cost and input costs.”
“There is more to do, but we have made real progress and our foundations are stronger.”
“a year of delivery against our strategic plan, of top and bottom-line growth and substantial cash returns to shareholders”
Where a supplier can help
- Plant upgrades and supply resilience
- Tied to the North America investment plan and the St. Peters downtime: suppliers of manufacturing equipment, line commissioning, maintenance and plant engineering can help bring new and upgraded lines on stream without further supply loss.
- Shared services and automation
- Tied to Fuel for Growth: the automation and shared services lever (hubs in Warsaw, Mexico City, Hyderabad) and SAP modernisation create openings for process automation, ERP and outsourcing partners.
- Input cost and packaging sourcing
- Tied to the Middle East input-cost challenge: suppliers of alternative solvents, plastics and post-consumer recycled packaging fit Reckitt's move to shift sourcing and build strategic inventory.
- AI and sales force tools in Emerging Markets
- Tied to the Emerging Markets priority: sales force automation and AI-enabled sales tools that widen distribution, as used in India, are being spread to other markets.
- Consumer trust and brand protection in China
- Tied to the China competition challenge: marketing, claims verification and media partners can support Reckitt's effort to restore trust in its US-manufactured VMS brands.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Reckitt?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Reckitt Annual Report and Accounts 2025
- Reckitt is a UK-headquartered consumer health and hygiene group (average 36k employees, operating in 80 countries) built around 11 Powerbrands in four Core Reckitt categories: Self Care (Strepsils, Mucinex, Gaviscon, Nurofen), Germ Protection (Lysol, Dettol, Harpic), Household Care (Finish, Vanish) and Intimate Wellness (Durex, Veet).
- FY2025 Group net revenue was £14,205mn, +5.0% like-for-like (price/mix +4.1%, volume +0.9%); Core Reckitt grew +5.2% LFL and Mead Johnson Nutrition (MJN) +3.8%. IFRS net revenue growth was +0.3% after -2.9% FX and -1.8% net M&A.
- Adjusted operating profit was £3,543mn at a 24.9% margin (+40bps); Core Reckitt adjusted operating margin was 26.7% (+90bps). Adjusted diluted EPS rose 1.1% to 352.8p; IFRS diluted EPS was 467.2p, lifted by the gain on the Essential Home sale.
- Emerging Markets is now the largest area (42% of Core Reckitt net revenue, £4,291mn, +14.6% LFL, margin 20.9%), led by China (double-digit) and India (high-single-digit). Europe declined -1.4% LFL and North America grew +0.2%.
- Portfolio reshaping: Essential Home (Air Wick, Calgon, Cillit Bang, Mortein, Woolite; £1.9bn net revenue) was sold to Advent on 31 December 2025, with Reckitt keeping a 30% equity stake; strategic options for MJN are still being assessed.
- Fuel for Growth cut fixed costs from 21.8% of net revenue in 2023 to 19.4% in 2025, targeting around 19% by end-2027 with approximately £1 billion of one-off transformation investment over 2024-2027; shared service hubs in Warsaw, Mexico City and Hyderabad and generative AI tools are the next sources of savings.
- Brand Equity Investment rose to 14.6% of net revenue (2024: 13.4%); total marketing was £2,337 million (16.5%). Launches include Durex Intensity (nitrile condom), Nurofen Mini Liquid Capsules, Dettol Activ-Botany and Lysol Laundry Sanitizer (a £300 million retail business).
- £2.3bn returned to shareholders in 2025 plus a c.£1.6 billion special dividend paid in February 2026; full-year dividend +5.0% to 212.2p; net debt £6,558 million at 1.6x adjusted EBITDA; free cash flow fell 23.4% to £1,709 million.
- Medium-term guidance: Core Reckitt +4% to +5% LFL net revenue growth with sustainable EPS growth. Heightened principal risks: product integrity, supply chain continuity, technology resilience/cyber, and geopolitical instability (tariffs, conflicts, shipping).
- Results for six months ended 30 June 2026 (Half Year 2026)
- H1 2026 (to 30 June) Group net revenue £6,411m, -8.1% IFRS after the Essential Home divestment, +2.6% like-for-like; Core Reckitt £5,110m, +2.7% LFL; Mead Johnson Nutrition £1,066m, +2.0% LFL.
- Growth accelerated in Q2: Core Reckitt +4.2% LFL (volume +2.0%, price/mix +2.2%), with all Areas and all Categories improving; excluding Russia Hygiene, Core Reckitt grew +3.4% in H1 and 4.9% in Q2.
- By Area (H1 LFL): Emerging Markets +8.5% (44% of Core Reckitt; China's 12th consecutive quarter of double-digit growth), Europe -3.0%, North America +0.8%.
- By Category (H1 LFL): Germ Protection +10.5% (Dettol, Lysol), Self Care +2.4%, Intimate Wellness +0.5% (VAT on condoms in China), Household Care -6.6% (Russia sanctions, Auto Dish promotions).
- Core Reckitt + MJN adjusted operating margin 23.6% (-100bps, ahead of expectations); gross margin 60.5%; Brand Equity Investment up 70bps to 15.3% of net revenue; adjusted diluted EPS 152.1p (-9.7%).
- Middle East war raised input costs; at Q1 a $110 oil scenario implied a c.£130 million - £150 million gross input-cost impact, since reduced. A £125 million loss was booked on classifying the Russian Hygiene business as held for sale.
- £3.0bn returned in H1 (including the £1.6bn special dividend); £6.4bn since July 2024; interim dividend 88.6p (+5%); new buyback of up to £500 million; net debt 2.5x adjusted EBITDA.
- FY2026 guidance kept: Core Reckitt +4% to +5% LFL, Core + MJN adjusted operating margin 24.9% to 25.6%, MJN low-single-digit growth; Fuel for Growth to bring fixed costs below 19% by end-2027.
- Q3 Results 2026 trading update: Powerbrands driving continued growth
- Q3 2026 (27 October 2026) Core Reckitt net revenue £2,690m, +3.3% like-for-like (+3.9% excluding Russia Hygiene); Total Group £3,362m, -6.9% IFRS because Q3 2025 included Essential Home (£479m).
- Emerging Markets £1,174m, +8.0% LFL (+9.8% ex Russia), all regions growing; India double-digit; China slowed to mid-single-digit on cross-border VMS headwinds.
- Europe returned to growth (+0.8% LFL) with Gaviscon, Vanish and Veet strong and Finish, Durex and Harpic back in growth; selective pricing for Middle East input costs.
- North America -1.3% LFL: temporary manufacturing constraints limited supply of Lysol despite strong demand, plus retailer order phasing; a rebound is expected in Q4.
- Category LFL in Q3: Germ Protection +6.0%, Intimate Wellness +6.4%, Self Care +2.2%, Household Care -1.5%; Mead Johnson Nutrition +2.7%.
- FY2026 Core Reckitt LFL guidance cut to +3.5% to +4.5% (from +4% to +5%); Core + MJN adjusted operating margin kept at 24.9% to 25.6%; Emerging Markets high-single-digit for the year.
- Up to $600m multi-year North America investment (innovation, Healthcare access, supply resilience); Russia Hygiene divestment expected in H2 2026; £90m of the £500m buyback done by 23 October.
- Net finance expense now £250m to £270m for 2026 (Mead Johnson bond tender) and £390m to £410m expected for 2027; tax rate 26% to 27%.
- Half Year 2026 results presentation and Q&A (edited transcript)
- Half-year 2026 results call (29 July 2026) with CEO Kris Licht and CFO Shannon Eisenhardt: Core Reckitt grew 2.7% like-for-like in H1 and 4.2% in Q2; full-year guidance of 4% to 5% held.
- Licht called Q1 "the anomaly in the year", caused by a weak cold and flu season, and expects the Q2 acceleration to be "the level that we're going to be performing at".
- Capital returns: GBP6.4 billion returned since the 2024 strategy, "around 20% of our market capitalization" at the time; a new GBP500 million buyback; the buyback size "will change over time" with capital allocation principles.
- Middle East war: the Bahrain plant was closed for staff safety and reopened; Reckitt is building strategic inventory of solvents and plastics, moving sourcing and using more recycled plastic.
- Pricing: single-digit price increases in some developed markets; Reckitt says its premium brands are "a little bit less exposed" to trade-down.
- Auto Dish in Europe is promotion-heavy "beyond levels that we actually believe are rational"; Reckitt will defend leadership but not match every deep promotion.
- China: 12 quarters of double-digit growth; Durex soft after VAT and content restrictions, expected to recover; a new Shanghai Science and Innovation Centre opened as the ninth global innovation hub.
- AI: token costs are "very small today"; the larger investment is in internal models and capabilities for productivity and growth.
- Q3 2026 trading update call (transcript)
- Q3 2026 trading update call (27 October 2026), CEO Kris Licht and CFO Shannon Eisenhardt: Core Reckitt +3.3% like-for-like, 3.9% excluding Russia hygiene; full-year guidance trimmed to plus 3.5 to plus 4.5%.
- Lysol: upgrades to lines at the St. Peters hygiene plant caused longer-than-expected downtime, "about four lines"; Licht stressed "this was not a demand issue". Sell-out was back to mid single digits in October.
- Licht: "We have not historically invested as much in manufacturing as a company as I think we need to"; the North America plan funds a new Self Care factory in North Carolina and upgrades to two hygiene plants.
- China VMS was roughly flat in Q3 after strong double-digit growth in H1, hurt by false claims from local competitors; Durex returned to growth.
- Seasonal OTC: US category sell-out up double-digit for five weeks; Mucinex 12HR Cold & Fever shows 85% repurchase intent.
- Pricing: "We will probably have to price more" if commodity costs stay high, with care where elasticity is high (household care in Europe).
- Finance: 2026 net finance expense £250 million to £270 million after the Mead Johnson bond tender, and £390 million to £410 million expected in 2027; margin guide 24.9% to 25.6% kept.
Questions about Reckitt
What does Reckitt do?
Reckitt makes consumer health and hygiene products under 11 Powerbrands, including Dettol, Lysol, Harpic, Finish, Vanish, Durex, Veet, Nurofen, Gaviscon and Mucinex. It operates in 80 countries and also owns Mead Johnson Nutrition, which it treats as non-core.
What is Reckitt's revenue?
FY2025 Group net revenue was £14,205mn, +5.0% like-for-like, with adjusted operating profit of £3,543mn. In H1 2026, after the Essential Home sale, Group net revenue was £6,411m.
How many employees does Reckitt have?
Reckitt employed an average of 36k people in 2025.
What is Reckitt's strategy?
Reckitt is focusing on Core Reckitt's Powerbrands, targeting +4% to +5% like-for-like growth over the medium term, while divesting non-core businesses and cutting fixed costs below 19% of net revenue by end-2027 through Fuel for Growth.
Who leads Reckitt?
Kris Licht is Chief Executive Officer, Shannon Eisenhardt is Chief Financial Officer and Sir Jeremy Darroch is Chair.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)